AMAALA Appoints HKS Architects Master Planner of Triple Bay and The Coastal Development
17.3.2020 10:00:00 EET | Business Wire | Press release
AMAALA, the ultra-luxury destination located along Saudi Arabia’s northwestern coastline, has announced the appointment of international design firm HKS Architects as Master Planner for Triple Bay and The Coastal Development. Set in the Prince Mohammed bin Salman Nature Reserve, AMAALA will bring to life the desires and ambitions of a community passionate about shaping, and living, transformative moments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200317005108/en/
The Coastal Development at AMAALA (Photo : AETOSWire)
Commenting on the appointment Chief Executive Officer of AMAALA, Nicholas Naples, said: “AMAALA will be a globally recognised destination for arts and culture, as well as one of the most comprehensive, integrative health, wellness, and sports offerings in the world. In partnership with HKS Architects, we look forward to realising our vision for Triple Bay and The Coastal Development by redefining the best in travel through the creation of transformative personal journeys for the world’s most discerning travellers.”
Triple Bay will offer a fully holistic wellness retreat, state-of-the-art diagnostic medical facilities, and authentic treatments influenced by the local environment and traditional practices. The community will be the first truly integrated sports and entertainment community with diagnostics, medical, and transformative wellness combined with learning in a family friendly environment.
With underwater experiences that will immerse guests directly into the natural domain of dolphins, turtles, and untouched coral reefs, Triple Bay is set to become one of the world’s finest diving destinations in the world.
The Coastal Development is set to become the defining hub of contemporary arts in the Middle East, playing host to a dynamic programme of exciting events from the global arts and cultural calendar. Built on philanthropy, the immersive programmes will be creative, practical, and academic with a strong link to the Saudi community.
The Coastal Development will feature an arts museum and cultural district dedicated to keeping ancient crafts alive, along with an amphitheatre for live performances. This stretch of coastline will be a gathering place for a community of influencers and connoisseurs, complete with premium spa facilities, yoga, meditation, in addition to an equestrian centre equipped to offer rehabilitation, high-tech stabling, tournament-grade polo facilities, and instructors.
Master Planning & Design Principal of HKS Architects, Kevin Underwood, said: “The developments at Triple Bay and The Coastal Development offer a once-in-a-career opportunity to shape a new tourism destination from the beginning and it’s a privilege to be involved as Master Planners. We’re bringing together the global expertise of our firm, using our knowledge of designing for healthcare, sports, and other uses allied to many years’ experience of working with luxury hotels and resorts to create something innovative and contemporary. Sustainability in all aspects is at the heart of our design, seamlessly integrating landscape and buildings with the stunning mountain and marine landscape of the Red Sea.”
AMAALA’s trio of communities – Triple Bay, Coastal Development, and The Island – will represent three different sets of experiences for visitors. The destination’s development will be rolled out in three key phases, with completion slated ahead of the realisation of Saudi Vision 2030.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200317005108/en/
Contact information
Hill+Knowlton
Muneira Al Adwani
Senior Account Executive, +97145539543
muneira.aladwani@hkstrategies.com
AMAALA
Julia Gajcak
Head of Communications and Events, +966532580725
jgajcak@projects.pif.gov.sa
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
